NASDAQ | ETF
Top 14 Holdings
| Asset | Name | Sector | Industry | Weight |
|---|---|---|---|---|
| VRTX | Vertex Pharmaceuticals Inc | Healthcare | Biotechnology | 5.24% |
| LLY | Eli Lilly and Company | Healthcare | Drug Manufacturers - General | 5.03% |
| NOVO-B | Novo Nordisk A/S | Healthcare | Biotechnology | 4.91% |
| AMGN | Amgen Inc | Healthcare | Drug Manufacturers - General | 4.57% |
| DXCM | DexCom Inc | Healthcare | Medical Devices | 4.07% |
| VKTX | Viking Therapeutics Inc | Healthcare | Biotechnology | 3.45% |
| BBIO | BridgeBio Pharma Inc | Healthcare | Biotechnology | 3.31% |
| EW | Edwards Lifesciences Corp | Healthcare | Medical Devices | 2.98% |
| MREO | Mereo BioPharma Group PLC ADR | Healthcare | Biotechnology | 2.95% |
| CYTK | Cytokinetics Inc | Healthcare | Biotechnology | 2.93% |
| 4519 | Chugai Pharmaceutical Co. Ltd. | Healthcare | Drug Manufacturers - General | 2.92% |
| MDT | Medtronic PLC | Healthcare | Medical Devices | 2.87% |
| RCKT | Rocket Pharmaceuticals Inc | Healthcare | Biotechnology | 2.78% |
| ASND | Ascendis Pharma AS | Healthcare | Biotechnology | 2.76% |
Under normal circumstances, the fund seeks to achieve its investment objective by investing at least 80% of its net assets, which include borrowings for investment purposes, in publicly listed companies that derive at least 50% of revenues from products or services related to the treatment of cardiovascular diseases and/or metabolic diseases, as defined by the Centers for Diseases Control and Preventions. The fund generally is expected to consist of more than 15 companies but not more than 100 companies. The fund is non-diversified.